Table 2.
Potential NAs mutation at 29 positions of HBV reverse transcriptase analyzed in the 73 pregnant women.
| Mutations type | Relationship with therapy | The proportion of the patients with mutations, n (%) (n = 73) | The frequency of the mutations∗ (%) | Patients with mutations frequency>20%, n (%) |
|---|---|---|---|---|
| Primary resistance mutations | ||||
| rtI169T | ETV | 0 | 0 | 0 |
| rtA181T/V | LAM, TBV, ADV, TDF | 4 (5.5) | 0.023 ± 0.020 | 0 |
| rtT184A/C/F/G/I/L/M/S | ETV | 52 (71.2) | 0.13 ± 0.14 | 14 (19.2%) |
| rtA194T | ADV, TDF | 0 | 0 | 0 |
| rtS202C/G/I | ETV | 1 (1.4) | 0.01 | 0 |
| rtM204I/V | LAM, ETV, TBV | 30 (41.1) | 0.13 ± 0.11 | 7 (9.6%) |
| rtN236T/A | ADV, TDF | 39 (53.4) | 0.10 ± 0.13 | 4 (5.5%) |
| rtM250I/L/V | — | 41 (56.2) | 0.11 ± 0.08 | 5 (6.8%) |
|
| ||||
| Compensatory mutations | ||||
| rtL80I/V | LAM | 11 (15.1) | 0.02 ± 0.01 | — |
| rtV173L | LAM | 0 | 0 | 0 |
| rtL180M | LAM, ETV, TBV | 0 | 0 | 0 |
|
| ||||
| Putative NAs mutations | ||||
| rtL82M | LAM | 0 | 0 | 0 |
| rtV84M | ADV | 2 (2.7) | 0.01 ± 0.001 | 0 |
| rtS85A | ADV | 0 | 0 | 0 |
| rtI91L | LAM | 40 (54.8) | 0.82 ± 0.30 | 36 (49.3%) |
| rtA200V | LAM | 1 (1.4) | 0.02 | 0 |
| rtV207I | LAM | 0 | 0 | 0 |
| rtS213T | ADV | 3 (4.1) | 0.11 ± 0.16 | 1 (1.4%) |
| rtV214A | ADV | 3 (4.1) | 0.01 ± 0.004 | 0 |
| rtQ215P/S | LAM, ADV | 12 (16.4) | 0.07 ± 0.08 | 2 (2.7) |
| rtL217R | ADV | 0 | 0 | 0 |
| rtE218D | ADV | 1 (1.4) | 0.52 | 1 (1.4) |
| rtF221Y | ADV | 30 (41.1) | 0.29 ± 0.25 | 16 (21.9) |
| rtL229G/V/W | LAM | 24 (32.9) | 0.05 ± 0.06 | 1 (1.4) |
| rtI233V | ADV | 30 (41.1) | 0.12 ± 0.11 | 7 (9.6) |
| rtP237H | ADV | 22 (30.1) | 0.02 ± 0.02 | 0 |
| rtN/H238D/S/T/A | ADV | 46 (63.0) | 0.15 ± 0.12 | 7 (9.6) |
| rtY245H | ADV | 1 (1.4) | 0.13 | 0 |
| rtS/C256G | LAM, ETV | 0 | 0 | 0 |
∗The prevalence of mutations were expressed as number of patients (percentages) and the mutation frequencies were expressed as mean ± standard deviation. Abbreviations: ADV, adefovir dipivoxil; ETV, entecavir; HBV, hepatitis B virus; LAM, lamivudine; n, number; NA, nucleoside/nucleotide analogues; TBV, telbivudine; TDF, tenofovir disoproxil fumarate.